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 Abstract 
Background 
Visceral leishmaniasis (VL) has been targeted by the WHO for elimination as a public health 
problem (<1 case/10,000 people/year) in the Indian sub-continent (ISC) by 2020. Bihar State 
in India, which accounts for the majority of cases in the ISC, remains a major target for this 
elimination effort. However, there is considerable spatial, temporal and sub-population 
variation in occurrence of the disease and the pathway to care, which is largely unexplored 
and a threat to achieving the target.  
Methods 
Data from 6,081 suspected VL patients who reported being clinically diagnosed during 2012-
2013 across eight districts in Bihar were analysed. Graphical comparisons and Chi-squared 
tests were used to determine differences in the burden of identified cases by season, district, 
age and sex. Log-linear regression models were fitted to onset (of symptoms)-to-diagnosis 
and onset-to-treatment waiting times to estimate their associations with age, sex, district and 
various socio-economic factors (SEFs). Logistic regression models were used to identify 
factors associated with mortality. 
Results 
Comparisons of VL caseloads suggested an annual cycle peaking in January-March. A 17-fold 
variation in the burden of identified cases across districts and under-representation of young 
children (0-5 years) relative to age-specific populations in Bihar were observed. Women 
accounted for a significantly lower proportion of the reported cases than men (41% vs. 59%, 
p-value <0.0001). Age, district of residence, house wall materials, caste, treatment cost, 
travelling for diagnosis and the number of treatments for symptoms prior to diagnosis were 
identified as correlates of waiting times. Mortality was associated with age, district of 
residence, onset-to-treatment waiting time, treatment duration, cattle ownership and cost of 
diagnosis. 
Conclusions 
The distribution of VL in Bihar is highly heterogeneous, and reported caseloads and 
associated mortality vary significantly across different districts, posing different challenges 
to the elimination campaign. Socio-economic factors are important correlates of these 
differences, suggesting that elimination will require tailoring to population and sub-
population circumstances.  
Key words: epidemiology of visceral leishmaniasis, burden of visceral leishmaniasis cases, 
Bihar, India, pathway to care, onset-to-diagnosis and onset-to-treatment times, mortality, 
statistical analysis 
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 Introduction 
Visceral leishmaniasis (VL) on the Indian sub-continent (ISC) is a disease caused by the 
protozoan parasite Leishmania donovani and transmitted from human to human by the 
female Phlebotomus argentipes sandfly. The symptomatic form of the disease, also known as 
kala-azar (KA), is characterised by fever, weight-loss and an enlarged liver and/or spleen, and 
has a case fatality rate of over 95%, if untreated [1]. In recent years, more effective treatments 
have reduced the case fatality rate to 10% on average [2], with studies suggesting that 
proximity to a previous VL patient, bed net usage and levels of insecticide spraying are 
important drivers of VL risk [3-5]. However, the role of delays in onset-of-symptoms to 
treatment has not been well quantified. The two main strategies for control are improved 
case detection and management (reductions in onset-to-treatment time), and indoor residual 
spraying with insecticide. 
 
The ISC has historically suffered the majority of the global burden of VL, with India, 
Bangladesh and Nepal accounting for 80% of the estimated 200,000-400,000 annual global 
cases between 2004 and 2008 [2]. However, since 2011 there has been a significant decline 
in the number of cases in the ISC [6-8]. Consequently, reduction of the incidence of 
symptomatic VL, to under 1 case/10,000 people/year at sub-district level in the ISC by 2020, 
is one of the WHO elimination goals. The governments of Bangladesh, India and Nepal have 
set a more ambitious goal of reaching the elimination target by the end of 2017 [9]. The state 
of Bihar in northern India is by far the most affected area within the ISC, accounting for 80% 
of VL cases in India [7] and is still far from elimination with recent estimates of 1-5 cases per 
10,000 per year at sub-district (block) level [10, 11].   
 
Over the last 50 years, reported national and regional VL incidence has oscillated in an 
approximately 15-year cycle [12, 13], with marked declines in recent years [14]. However, 
there is some evidence of spatial variation in incidence rates [11, 15], the causes of which are 
poorly understood. Previous studies have found evidence of seasonal variation [3, 12, 16-22], 
measured by incidence of diagnosis or numbers of sandflies, but the resulting inferences 
made on VL incidence are complicated by long incubation periods, an uncertain proportion of 
asymptomatically infected humans and long durations until diagnosis [23]. There have also 
been few systematic studies of seasonality across multiple areas with different incidence 
rates. Variations in incidence by both age and sex have also been inferred from many previous 
studies [3, 5, 12, 21, 22, 24-28], but the majority of these are either single-location studies or 
based on small numbers of cases. Differences in incidence by location, age and sex have often 
been hypothesised to be due to differences in access to care, both in terms of individual 
effects and the indirect effect of long onset-to-diagnosis times on transmission. However, 
there are few studies of large patient groups investigating drivers of onset-to-diagnosis or 
treatment patterns [29].   
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As the VL control programme in Bihar builds towards achieving elimination as a public health 
problem, and, in the longer term, maintaining this goal and aiming for elimination of 
transmission, there is a shortage of quantitative information on variation in case burden and 
drivers of delays in diagnosis. By quantifying these factors across multiple settings, we aim to 
characterise key sources of variability and inform the design of control programmes to 
identify and treat the final cases.  Using records from 6,081 suspected VL patients in 8 districts 
in Bihar, we highlight significant variations in the burden of identified cases (the number of 
cases identified per head of population per year) and mortality. Although incidence of VL has 
been the main focus of most previous studies, we additionally study the pathway to care of 
infected individuals. The large number of symptomatic cases in our dataset, together with the 
multiple locations and detailed information on socio-economic factors (SEFs) such as housing 
and cattle ownership, allow us to perform a thorough analysis identifying key differences in 
VL patients’ pathway to care and odds of survival.  
     
Material and Methods 
Data collection 
Study population and VL case tracing 
CARE India, a non-governmental organization, undertook a rapid situational assessment of VL 
in 2013 to inform the operation of the kala-azar elimination programme in Bihar. The 
assessment was conducted as part of the intervention programme funded by the Bill and 
Melinda Gates Foundation (BMGF) in eight (out of a total of 38) districts of Bihar – including 
both high and low endemicity districts. Only eight districts were selected due to resource 
constraints and the need for a rapid assessment, and due to CARE India having existing 
infrastructures for conducting field research in these districts. Due to operational feasibility 
the case tracking was limited to symptomatic VL patients only. The reference period for the 
assessment (the period during which VL diagnosis took place) was between January 2012 and 
June 2013. The following combination of methods was followed to meet this objective (data 
collection and processing are also described elsewhere [30]): 
I. Index case tracing and snowballing: Line lists of VL patients, whose date of diagnosis 
was within the reference period, reported by the state-run health facilities (block and district 
hospitals) were compiled. In addition, healthcare facilities belonging to the study area, which 
specialized in kala-azar care, were contacted to obtain information on potential VL cases. 
Cases obtained from these two sources were checked to identify and remove duplicates. 
Attempts were made to trace every patient whose name appeared on the compiled list.  
An interview was conducted by a trained study investigator with the successfully traced 
patient or his/her family members. A medical record review, for patients who possessed any 
documents pertaining to diagnosis and treatment for VL, was conducted along with the 
interview. Additionally, patient/family members were requested to provide information on 
any other potential cases of VL in the family or neighbourhood. Contact information of such 
suspected patients was collected. If a patient could not be traced to the particular address, 
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the case information was shared with other districts in the study, and if the patient could still 
not be traced, the case was considered untraceable. 
Additionally, to increase the sensitivity of the case finding effort, some key informants (such 
as community health workers and school teachers) from the villages mentioned in the address 
of potential cases were interviewed to determine if they were aware of any other VL patients 
or cases of prolonged fever during the reference period, either amongst residents of the same 
village or elsewhere. Contact information of any such suspected cases was also collected. 
 
II. Mapping and interviewing private healthcare providers: A mapping exercise was 
undertaken to identify all private laboratories and pharmacists in all villages/towns of each of 
the study districts. These private healthcare providers were then interviewed to ascertain if 
they had diagnosed or dispensed medications to any VL patient during the reference period. 
Moreover, all qualified doctors, and all unqualified practitioners with a large clientele, who 
were captured through the provider mapping exercise, were contacted to obtain information 
on any VL patients they had seen or treated (either confirmed or with VL-like symptoms)  
 
The list of potential additional cases generated in this manner was compiled and screened for 
duplications and repetitions of known cases from government reported lists, and individuals 
that remained on the non-duplicate list were considered ‘suspected’ VL cases. An attempt 
was made to trace each suspected case to his or her residence and interview him or her or 
his/her family, where any documentary proof of diagnosis or treatment was collected. These 
suspected cases were also asked about any other cases of VL or prolonged fever that they 
may have known. This iterative process continued until all suspected cases had been 
interviewed.   
 
All available details of such suspected cases were recorded. No attempt was made to clinically 
examine suspected cases or confirm their diagnosis through laboratory tests. 
 
The breakdown of the sources via which patients were identified is shown in Table 1. Fourteen 
per cent of cases reported by the national control programme (i.e. those reported by the 
state-run health facilities) were untraceable. However, approximately 15% of cases identified 
by the case tracing process were not recorded by the national programme, suggesting that 
the official figures provide an underestimate of the true VL burden, though much less of an 
underestimate than suggested by previous studies [31, 32]. 
 
VL case definition  
A patient was considered to be a case of VL if he/she met any of the following criteria: 
1. If the patient’s name and address was included in the line list of VL patients who were 
diagnosed by any government facility within the reference period and he/she could be traced 
to the listed address, regardless of possession of any documents related to diagnosis or 
treatment. 
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2. If a potential case possessed any documents, from private or public facility, confirming 
his/her VL diagnosis (serologic test, splenic/bone marrow biopsy) within the study reference 
period. 
3. If a potential case possessed documents demonstrating VL treatment – such as 
prescriptions/pharmacy slips/drug packaging that indicated treatment with miltefosine, 
sodium stibogluconate (SSG) or amphotericin B - and start of treatment occurred within the 
reference period.  
 
Participant interview 
A face-to-face interview was conducted with every eligible VL patient identified using the case 
detection methodology. If a patient died in the interim, the interview was conducted with the 
next-of-kin. Data was collected on, inter alia, socio-demographic characteristics (age, sex, 
district), date of onset of symptoms, place and date of diagnosis, pre- and post-diagnosis 
treatment history, and type and duration of drug treatment. Whenever available, information 
on treatment and diagnosis history was recorded from the medical documents. Data was 
entered using the Census and Survey Processing System CSPro 5.0, and assessed for logical 
inconsistencies and to detect and remove duplicate entries. 
 
Statistical analyses 
Our analyses were conducted using data from the retrospective clinical case finding and 
patient questionnaires described above. This dataset consists of information on 6,081 
suspected VL cases. A flow chart showing the inclusion criteria for VL cases for the statistical 
analyses is presented in Figure 1. 
 
Burden of identified cases; seasonal and district-specific variation and age distribution: 
Unlike some previously reported studies [3, 4] all individuals in the CARE dataset were 
symptomatic patients. The lack of a control group of disease-free individuals meant that 
analyses to determine the association of SEFs, such as housing or cattle ownership, on VL risk 
were not possible. To compare the burdens of identified VL cases in different districts, the 
expected proportion of VL in each district was computed as being equal to the population 
proportion (of the eight districts combined) and a Chi-squared test was used to judge the 
collective significance of differences between observed and expected case burdens. Using 
2011 census populations by district [33], the sex distribution of cases was analysed following 
a similar procedure and the district age distributions of cases were compared. Monthly 
numbers per district of onsets and diagnoses in 2011-2013 were computed and plotted to 
examine seasonal variation. 
    
Variation in the pathway to care and mortality: 
The data included information on house construction and size, wall, floor and ceiling 
materials, cattle ownership and financial contributions to diagnostic tests and treatment. All 
of these could be viewed as surrogate indicators of economic status and many could influence 
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the pathway to care. Thus, the effects of variations in housing, cattle ownership and paid-for 
vs. free services on onset-to-diagnosis (OD) and onset-to-treatment (OT) waiting times were 
analysed together with age, sex and district. As both waiting times have right-skewed 
distributions (Figure 6) with variances much larger than their means (variance/mean = 47.06 
days and 38.46 days for the OD and OT times respectively), negative binomial regression 
models with exponential link function were used to analyse them. Due to the finite sampling 
period, there was a bias towards elongated waiting times at the start of the sampling period 
and shorter waiting times at the end, therefore we restricted the analysis to the central 
portion of the data time-period (details in Results). First single-variable models were fitted to 
eliminate the least significant relationships, then multi-variable models for comparison 
purposes. Starting with all variables judged significant in single-variable models, factors were 
accepted or rejected using the likelihood-ratio-test (LRT). Using a logistic regression model, 
with a similar selection procedure, we investigated the effects of the same set of factors 
together with OD and OT waiting times on patients’ risk of death. Although no information as 
to causes of individuals’ deaths was available, death rates appeared to be both much higher 
and differently distributed over age and sex amongst patients than in the general Bihar 
population, such that it seems likely the excess mortality was VL related. To increase 
understanding of factors influencing overall mortality amongst VL patients, we consequently 
analysed the risk of dying of any cause during the study period. All regression analyses were 
performed using Stata 14 [34]. 
 
Results  
A total of 6,081 suspected VL cases from 131 blocks in eight districts of Bihar were identified 
in the VL situational assessment. One hundred and fifty-one cases were recorded as having 
post kala-azar dermal leishmaniasis (PKDL) and were excluded from all analyses due to 
uncertainty about whether their illness and treatment data referred to VL or to PKDL. Among 
the 5,930 cases remaining, 59% were male and 41% female; median age was 20, varying from 
16 to 30 between districts (see Additional files 1 and 2). 
 
Burden of identified cases: 
Monthly counts of diagnoses in January 2012-June 2013 by district are displayed in Figure 2a. 
The monthly numbers of cases by onset for each district have been plotted from the patients’ 
self-reported onset dates in Figure 2b. Since inclusion in the study was based on the date of 
diagnosis being between 1st January 2012 and 30th June 2013, there was an inherent bias 
towards longer OD times amongst cases with onset prior to 2012, and towards shorter OD 
times amongst cases with onset after June 2013 (see figure in Additional file 3). Hence, these 
cases were excluded from the analysis. Patterns of monthly case numbers in most districts in 
2012-2013 suggest an annual cycle peaking early in the year (Figure 2b), though differences 
between the two years’ and eight districts’ maximum and minimum values make it difficult 
to establish a consistent seasonal pattern. 
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For comparison of identified case burden between districts, the total population of the blocks 
in each district with at least one case in January 2012-June 2013 [35], defined by date of onset, 
were used to compute the case burden in 2012-2013. Displayed in Table 2 in decreasing order 
of number of cases, the district burdens of identified cases varied 17-fold from about 1/2,000 
to 3/100,000. This variation was particularly marked in Saharsa with cases per head almost 3-
fold larger than any other district, and Patna and West Champaran, where cases per head 
were 3-fold lower than any other district. The Chi-squared test statistic comparing observed 
and expected numbers was very large at 4143.7 (p-value<0.0001 at 7 degrees of freedom), 
indicating that relative per-district reported numbers of cases are very different to those 
expected from their populations alone. To look for relationships between waiting times and 
relative case counts, yearly district case burdens in January 2012-June 2013 (computed as 
annual-number-of-cases/10,000 of population) were plotted against median OD and OT times 
in Figure 3. Although there was no apparent positive or negative relationship, this does not 
necessarily mean that reducing waiting times does not lead to significant reductions in case 
burdens, as there will be a lag before the impact on the case burden is observed. Furthermore, 
districts that have high case burdens may have shorter OD and OT times due to greater 
awareness and surveillance of VL, and vice versa for districts with low case burdens. 
 
The maps of Bihar in Figures 4a and 4b show the total numbers of identified VL cases with 
onset between January 2012 and June 2013 at district level and block level, respectively. 
Equivalent maps for the burden of identified cases at district and block level are provided in 
Additional file 4. It is clear from these maps that there is considerable spatial heterogeneity 
in the occurrence of VL. The block-level maps reveal that there is large variation in the 
identified burden within high-burden districts, with cases per head per year ranging from 
1.69/10,000 to over 9/10,000 in blocks in Saharsa and 0.04-6.17/10,000 in East Champaran, 
with a small number of blocks contributing the majority of the overall burden in these 
districts. Whilst there appears to be some spatial correlation in reported caseloads at block 
level (Additional file 4), there are also blocks with large numbers of identified cases 
neighbouring blocks with very few cases. 
 
Age and sex distributions: 
As illustrated in Figure 5a, the age distribution of patients did not vary significantly between 
districts, despite large variability in case counts. For most districts, the proportion of overall 
cases increases from age 0 to a maximum in 10-14 year-olds, then decreases quickly up to 
around age 20, and thereafter decreases more slowly with age. Most districts showed a 
notable lack of juvenile cases, compared with the corresponding population age distribution. 
While the cumulative age-distribution of the eight districts shows a general decrease with 
age, the cases-per-head was only 10.32/100,000 among 0-5 year-olds increasing to 
27.81/100,000 in the 10-14 age group, before dipping and then increasing to 26.28/100,000 
in the 60-64 age group (see Table 3). A Chi-squared test comparing male and female patient 
numbers of 3,501:2,422 with population proportions of 14,737,088:13,445,449 gave a 
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statistic of 109 (p-value<0.0001 at 1 degree of freedom), suggesting that men have 
significantly higher chances of being diagnosed with symptomatic VL than women. Comparing 
the burden of identified cases by age group for males and females (see Figure 5b) showed 
that the under-representation of VL in children was common to both sexes and that the lower 
rates in females were due to the numbers of reported cases in adult women being reduced 
relative to men, particularly in older age groups, rates in the 0-14 age range being nearly 
identical.        
 
Variation in the pathway to care: 
The district-specific distributions of OD lag, OT lag and treatment durations are illustrated in 
Figure 6 and their summary statistics are given in Table 4. Very little difference in treatment 
duration was observed, with patients in all districts undergoing a median of four weeks 
treatment. OD and OT time varied more, from 16.5 and 17 days in Begusarai (IQR 7-32 and 8-
31) to 55 and 45 days (IQR 30.5-80 and 25-90) in West Champaran. Perhaps counterintuitively, 
patients appeared to wait slightly longer on average for diagnosis than for treatment (median 
31 vs 30 days); however, this can be attributed to the delay between clinical examination and 
diagnostic testing for VL and official confirmation of the VL diagnosis.  Treatment for VL, as a 
high-mortality-rate disease, is likely to have begun shortly after the patient presented with 
symptoms, but the official diagnosis may not have been recorded until one or two days later. 
Additionally, the reliance on self-reported onset dates and treatment durations is likely to 
have introduced some uncertainty into the reported waiting times. 
 
A number of factors were associated with variation in OD and OT waiting times. The 
magnitudes of the effects of age, sex, district, housing and diagnosis/treatment facility are 
displayed in the table in Additional file 5 as regression model rate-ratios. Waiting times were 
estimated to increase by 0.4% and 0.5% respectively for every year increase in age. OD time 
was estimated to be up to 3.2 times longer and OT time 2.9 times longer in other districts 
relative to Begusarai, the district with the shortest average waiting times. Living in a mud-
walled house was found to be associated with an 11-12% reduction and stone-walled house 
with a 6% increase in both waiting times relative to houses with other wall types. Cattle 
ownership was associated with a 5% decrease in OD time, while having a house with more 
than two rooms was estimated to confer a 19-23% increase in waiting times. Paying for 
diagnosis and being diagnosed at a private centre had near identical effects, with both waiting 
times appearing to be shorter for individuals choosing to use free services. Being lower-caste 
was also associated with a 10-11% reduction in waiting times. Patients’ travelling outside their 
block of residence was estimated to confer a 15-18% increase in their waiting times, while the 
effect of travelling outside their home district appeared to be smaller but still significant at 
12-13%. Relative OD and OT waiting times appeared reduced for 1 or 2 pre-diagnosis 
treatments (PDTs) and significantly increased for 4 PDTs, with rate-ratios rising from 0.53-
0.66 for one PDT to 1.21-1.51 for four PDTs. Effects of gender, house type, roofing and flooring 
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materials and public vs. private treatment did not show any significant association with either 
waiting time. 
 
In the multi-variable model, house size, cattle ownership, diagnosis cost and public vs. private 
diagnosis were eliminated from both waiting-time models. Treatment cost and same-block 
diagnosis were not significantly associated with OD and caste was not significantly associated 
with OT in the multi-variable model (see Table 5 for the optimised models and their 
covariates’ relative risks and p-values). In combination with other factors, the effect of paying 
for treatment appeared to be reversed, moving from an increase of 5-8% to a reduction of 8% 
(95% CI 0.87-0.97).  Waiting times were still estimated to increase with the number of pre-
diagnosis treatments, much more so for OD with rate-ratios from 1.64 (95% CI 1.22-2.21) for 
1 PDT to 3.70 (95% CI 2.73-5.00) for 4, slightly more for OT, from 1.04 (95% CI 0.82-1.31) for 
2 PDTs to 1.71 (95% CI 1.35-2.17) for 4. The measures of association for age, district, wall 
material, caste and travelling for diagnosis remained similar to those observed in the 
univariate model analyses. When interactions between variables were added to the model, 
no significant improvement in goodness-of-fit was observed.   
 
Factors influencing mortality rates:  
Analysis of age- and sex-specific death rates among VL patients with onset of symptoms in 
2012 revealed that for 0-14 year-olds mortality was higher among females than males, with 
the pattern reversed in adults (see Table 6). Even though all patients within the study were 
assumed to have received treatment, death rates were still much higher in all age groups and 
both sexes amongst patients than the general Bihar population (apart from women over the 
age of 60) in 2012 [36], and showed different patterns with age and sex more closely 
resembling the age-sex distribution of VL cases. This suggests that VL patients had an elevated 
risk of dying, as noticed in previous studies [37], and factors underlying this were thus worthy 
of investigation. 
 
Comparison of p-values and log-likelihoods for univariate logistic models indicated that sex, 
all housing factors, free vs. paid-for treatment or public vs. private facilities, caste the number 
of pre-diagnosis treatments and diagnosis within vs. without block and district-of-residence 
had no significant association with risk of death. By backwards selection starting from a model 
incorporating age, district, waiting times, cattle ownership and free vs. paid-for diagnostic 
test, death risk was subsequently shown to have no significant association with OD time (see 
Table 7 for the optimised model and the covariates’ relative risks and p-values). The greatest 
risk-reducer appeared to be cattle ownership, conferring a 39.4% reduction, and free 
diagnosis was associated with a more than two-fold increase in mortality risk, with an odds-
ratio of 2.19, although the confidence intervals (CIs) of both odds-ratios were quite wide at 
0.44-0.85 and 1.49-3.21 respectively. Each additional year of age was associated with a 3% 
increase in risk (95% CI 1.025-1.04) and each extra day waiting for treatment conferred a small 
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but significant 0.6% increase (95% CI 1.002-1.09). Although there are possible confounding 
factors, death risk was estimated to decrease by 9% per day of treatment (95% CI 0.89-0.93).    
 
Forward selection exploring models with pairwise interactions between district and other 
factors found no significant variation in associations between districts. Similarly, models 
incorporating interactions between multiple housing-material factors did not fit significantly 
better than those without interactions. 
 
Discussion 
This study is one of few to assess variation in VL case burden in Bihar and the first to examine 
the spatial differences and effects of socio-economic factors (SEFs) on VL mortality rates, 
diagnosis and treatment in the ISC, highlighting important variability in the pathway to care. 
 
Burden of identified cases; spatial, seasonal, sex- and age-specific variations: 
Although calculation of district-specific incidences was not possible due to insufficient 
knowledge of the population- and person-time- at-risk, comparing case counts of some 
districts with their respective populations shows that there are significant differences in 
their burdens of identified cases. The districts with the highest and lowest numbers of 
reported cases were Saharsa and West Champaran respectively, despite the latter having 
the larger population. There is also strong spatial heterogeneity in the numbers and burdens 
of identified cases at block level, with greater variation in block burdens than district 
burdens. 
At state-level there has been a significant decline in the number of reported VL cases in 
Bihar since 2011 (from 25222 cases in 2011 to 4773 cases in 2016) [7], and in all districts in 
this study apart from West Champaran the total number of identified cases decreased 
between January-June 2012 and January-June 2013 (Figure 2b). There are various factors 
that may have contributed to this decrease. One is greater availability and awareness of free 
diagnosis and treatment in government health centres [38] and shorter times to treatment 
(c.f. Table 4 with Table 1 in [39]), which may have led to significant reductions in 
transmission by shortening the periods for which VL cases are infectious. Another is 
reported increased coverage of indoor residual insecticide spraying (IRS) [28, 40], which may 
have reduced transmission by reducing sandfly densities. However, whether IRS coverage in 
the eight study districts increased prior to 2012 is uncertain, and there is evidence of sub-
standard IRS implementation and widespread sandfly resistance to DDT 
(dichlorodiphenyltrichloroethane, the insecticide used at the time) in Bihar [41-43]. Given 
the long-term cycles in reported case numbers [12, 13], it is also possible that much of the 
decrease is due to long-lasting immunity having built up in populations affected during the 
previous epidemic in the late 2000s, such that the the pool of susceptible individuals who 
can become infected and develop VL has been depleted [44]. 
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The annual cycle observed in 2012-2013 monthly onsets and, to a lesser extent, in monthly 
diagnosis numbers, is almost certainly attributable to seasonal variation in sandfly 
populations. The majority of previous studies of seasonal variation in sandfly numbers found 
the vector density to be positively correlated with temperature and negatively correlated with 
rainfall [16-19]. Peak populations were recorded in summer and after the end of the rainy 
season, although with variations (March-April and November [16], May-July and October-
November [17], March-May [18], and June-July and November [19]). The summer (March-
May) peak appears to coincide with that seen both in the monthly onsets in this study and in 
other studies examining VL seasonality, which found cases to peak in March-April [20, 22]. 
This is unexpected; given an infected-symptomatic sojourn time of 2-5 months [3, 15, 23, 45], 
one would expect cases to peak later in the year than sandfly density, and indeed some 
studies have observed highest numbers of VL cases in July-September or in April-June and 
lowest numbers in January-March [3, 12, 18, 21]. However, the peak in cases in March-April 
fits with the peak in sandfly abundance after the rainy season (October-November) in the 
previous year. One possible explanation for the lack of a second case peak after the summer 
sandfly peak could be that the proportion of infective sandflies only peaks once, late in the 
year [46]. Variation in the timing and appearance of the case peak is likely to be due to the 
considerable variation in the incubation period for disease (since longer incubation periods 
dampen the seasonality in the number of cases from that in the sandfly abundance [47]). 
However, the previous studies suggesting a later peak incidence than our analyses had some 
weaknesses as ascertainers of seasonality - the studies by Bern and Perry et al [3, 21] were 
both cross-sectional studies with relatively low numbers of actual symptomatic VL patients 
and it is likely that the historic case counts used by Bora [12] are numbers of diagnoses rather 
than of onsets, which could easily explain the relative delay in peak cases via the added OD 
waiting times. Although both onset and diagnosis numbers in our data show an annual cycle, 
the oscillation is much less clear in the monthly diagnosis numbers. This adds uncertainty to 
the seasonality reported by Bora [12] and suggests that added variation from factors such as 
waiting times can easily distort/cloud the results of diagnosis tests as a representation of 
temporal VL distribution, and thus that future studies examining symptomatic VL 
epidemiology might be better using patients’ records of their disease progression, as used 
here, rather than clinical test results, even accounting for the greater measurement errors 
associated with self-reported/questionnaire data. To overcome the uncertainty about the 
relationship between seasonally varying sandfly and case numbers, the two need to be 
measured simultaneously and a better understanding of asymptomatic sojourn times is 
needed. 
          
As illustrated in Figure 5a and Table 3, young children are noticeably less affected by VL 
relative to the age distribution of the general population. Although this is in contrast to the 
study by Perry et al [21] which estimated the 0-10 age group to be at highest risk and the 11-
20 age group at lowest risk of VL, Perry et al [21] only included 45 symptomatic VL cases and 
a reduced incidence of VL in young children has been observed in the majority of previous 
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studies [3, 5, 12, 22, 24, 27, 28]. If the apparently low burden of cases in under-5s does reflect 
the actual underlying age distribution of disease, a possible explanation is variation in sandfly 
exposure – via different patterns of daytime movement or prioritisation of bed nets, young 
children have lower levels of VL infection because they are less frequently bitten by sandflies. 
Another hypothesis for under-representation is under-reporting of symptomatic VL in 
children – in regions where there are many infant deaths due to fever, many fatal VL cases in 
infants could have been passed over when collecting our dataset. This is suggested by Bihar 
population surveys reviewed by Bora [12], where the 1989 number of cases in the 0-9 age 
group is 8.6% higher than that in 1979 - given that the population-wide case counts are similar 
in the two years, it is possible that an apparent increase in children is due to a reduction in 
under-reporting rather than an actual change in age-specific levels due to the long-term 
dynamics of the disease. It is also possible that there is little variation by age in actual biting 
and infection rates, but children have a lower probability of an asymptomatic infection 
developing into clinical VL, so are consequently rarer in the symptomatic population.  
 
The hypotheses of lower exposure of susceptible individuals or of lower probability of 
infected individuals becoming symptomatic could also account for the apparent reduction in 
VL cases among women relative to men, also reported by previous studies [3, 5, 12, 21, 22, 
24-27, 48]. Another possible explanation is under-reporting of female cases due to women 
having, on average, poorer access to appropriate healthcare. This hypothesis is supported by 
Alvar et al [49], where 60–80% of health facility patients were male while sex ratios were 
almost equal in population-based studies. This theory could also explain why only adult 
women appear to have reduced risk – before the age of 15, say, males and females are equally 
likely for their parents/guardians to take them to a doctor when unwell, while adult women 
are less able than men to travel to healthcare facilities. Given that our analyses of factors 
affecting waiting times for diagnosis and treatment (discussed in more detail below) found 
no significant difference between sexes, it would seem probable that reduced access to 
healthcare for women is more likely to have manifest as a lack of, rather than a delay in, 
diagnosis and treatment for some symptomatically infected women. The apparent widening 
of the gap between the numbers of identified cases in men and in women with age in our 
data is strikingly similar to that observed in a study of 8749 VL patients from the Vaishali 
district of Bihar [22], and emphasises the need for further investigation of the factors affecting 
reported numbers of male and female cases. 
 
Significant differences in the pathway to care 
In our analyses of waiting times, we found significant differences between districts even after 
the inclusion of many SEFs one might expect to account for such variation. Given that several 
SEFs found to be significant in univariate regression models were subsequently excluded from 
multivariate models, this could be because an individual’s district is a more informative 
(summary) measure of their effective socio-economic status than any available single SEF and 
as such, the spatial association might be replaceable by the right combination of SEFs. 
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Alternatively, the observed association might be attributable to unmeasured variation in 
health provision between districts; this could include healthcare staffing levels and VL 
awareness as well as documented statistics such as relative availability of public health 
centres. Out of the other factors judged to have significant effects, having more PDTs or 
having to travel outside one’s residential area were unsurprisingly estimated to increase both 
waiting times. Somewhat unexpectedly, paying for treatment appeared to decrease OT 
waiting times only when in combination with other variables, and lower-caste individuals 
were estimated to have shorter diagnosis and treatment waiting times on average. The 
apparent reduction in waiting times for lower-caste individuals is likely also due to a 
difference in awareness – as VL is a disease associated with poverty, clinical practitioners 
might be more likely to VL-test and medicate a lower-caste patient with a fever.    
 
Mortality:  
Another important issue for minimising the effects of VL as a public health problem is the 
reduction of mortality related to the disease. To develop strategy for this, it is necessary to 
understand which factors significantly influence mortality among patients. Comparing the 
effects of numerous factors on an individual’s probability of death using logistic regression 
models, somewhat surprisingly no significant difference was found between sexes or 
different housing types and materials. The increase of mortality with age was unsurprising, as 
was the small but significant increase with waiting-time to treatment. The associations 
between increased treatment duration and cattle ownership and lower mortality are more 
difficult to interpret – the former might be biased by some individuals only receiving longer 
treatments because they survived the pre- or early-treatment stage, while cattle ownership 
might be directly protective via better nutrition but alternatively could just be a marker of 
higher average socio-economic status. The lower mortality among patients paying for 
diagnosis could be wealth-related – higher-income individuals might be more likely to pay for 
care, or facilities providing free diagnosis tests might be more accessible in poorer areas, with 
differences in mortality thus attributable to differences by wealth in average baseline health. 
Due probably to the low numbers of VL patients and thus even lower number of patient 
deaths observable from case-control studies, there appear to be very few previous studies 
examining factors affecting mortality rates amongst VL patients. Barnett et al [25] and Huda 
et al [50] both reported differences in male and female mortality rates, whereas sex was not 
found to significantly affect death risk in our regression analyses. However, these two studies 
actually suggested opposing results; 33% vs. 75% of deaths among males, and were based on 
very low numbers of deaths; 8 and 9 respectively. Similarly to our own analyses, a recent 
study using the same data source, by Das et al [30] found cattle ownership and shorter onset-
to-diagnosis waiting times to be associated with a reduced death risk and age and private 
treatment associated with an increased risk, but gender to have little effect. Although the 
results in Das et al [30] also suggested that house-type and caste affected mortality while 
these were eliminated from our preferred model, this is likely due to a difference in methods; 
Das et al measured variations in death risk over time using Cox proportional hazard models 
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while our analyses were of the total hazard of dying. Consequently it could be that caste 
and/or house type have a significant effect on time-dependent risk of death but not the 
overall risk. Alternatively, the inclusion of district in our regression analyses might have 
accounted for variations in mortality attributed to housing or caste in [30]. 
       
Our analyses did have several limitations. The lack of information on disease-free individuals 
prevented any investigation of the effects of SEFs on VL incidence across Bihar. The usage of 
retrospective questionnaires for data collection meanwhile meant that records of both key 
dates along the pathway to care and some SEFs were incomplete and sometimes 
contradictory, whilst the records of deaths within the study did not differentiate between 
deaths caused by VL and those from other causes. Nevertheless, we were able to gain 
valuable insight into the effects of housing, cattle and location on VL diagnosis and treatment 
as well as variations in the distribution of the disease itself.  
 
Conclusions 
The conclusions of this study are that in various VL-endemic districts of Bihar there remain 
challenges in elimination of VL and that there is considerable variation between regions in the 
pathway to care. For long-term control, more attention needs to be focused on districts with 
a high case burden, and efforts should be made in all regions to reduce waiting times for 
diagnosis and treatment, either by increasing provision or awareness, and to improve 
healthcare access for women. 
 
Additional Files 
Additional file 1: Table of distribution of socio-economic factors across the eight study 
districts. 
Additional file 2: Table of distribution of continuous variables; age, waiting times and house 
size, by district. 
Additional file 3: Box-plots of distribution of onset-to-diagnosis waiting times by season of 
onset. 
Additional file 4: Maps of Bihar showing burdens of identified cases in study districts for 
January 2012 - June 2013 at (a) district level and (b) block level. 
Additional file 5: Single-variable negative-binomial regression models for OD and OT waiting 
times. 
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Figure legends: 
 
Figure 1: Flow chart for inclusion of VL cases in statistical analyses. OD = onset-to-diagnosis, 
OT = onset-to-treatment, NB = negative binomial. 
Figure 2: Number of VL diagnoses per month and district (a) by date of diagnosis, (b) by date 
of onset of symptoms. Data were collected on cases diagnosed between January 2012 and 
June 2013, and therefore incidence outside these periods is marked by a grey box. 
Figure 3: Annual burden of identified cases by district plotted against (a) median onset-to-
diagnosis (OD) time and (b) median onset-to-treatment (OT) time. 
Figure 4: Maps of Bihar showing total numbers of identified VL cases in the 8 study districts 
between January 2012 and June 2013 at (a) district level and (b) block level. 
Figure 5: Age distribution of cases. (a) Proportion of cases in 5-year age groups by district 
and (b) proportions of male and female cases in 5-year age groups across all 8 districts. 
Figure 6: Distributions of (a) onset-to-diagnosis (OD) and (b) onset-to-treatment (OT) 
waiting times by district. 
Tables: 
Table 1: Sources via which VL cases were identified 
Primary source via which case was identified Number Percentage 
Official list from block PHC/SDH/FRU* 3,835 63.07% 
Official list from other block PHC/SDH/FRU 231 3.8% 
Official list from district hospital 1,021 16.79% 
Official list from government medical college 5 0.08% 
Official list or patient of RMRI** 7 0.12% 
Laboratory 31 0.51% 
Private hospital/doctor 126 2.07% 
Chemist/Pharmacist 23 0.38% 
Another patient 361 5.94% 
Key informants# 388 6.38% 
Self-informed by patient 53 0.87% 
Total 6,081 100% 
* PHC = Primary Health Centre, SDH = Sub-Divisional Hospital, FRU = First Referral Unit 
** RMRI = Rajendra Memorial Research Institute, Patna, Bihar 
# Key informants = Accredited Social Health Activists (ASHAs), villagers, friends, relatives 
 
Table 2: Comparison of burden of identified VL cases in 8 districts of Bihar, 
January 2012 – June 2013 
District Total 
population 
of affected 
blocks* 
Number of VL 
cases 
identified 
Number of VL 
cases with 
onset between 
Jan 2012 & Jun 
2013 
Burden of 
identified cases 
(cases/10,000/year) 
Chi-
squared 
statistic 
Saharsa 1,900,661 1,639 1,447 5.075 3012.16 
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E. Champaran 5,099,371 1,383 1,214 1.587 38.45 
Samastipur 4,261,566 925 862 1.348 0.189 
Gopalganj 2,562,012 799 666 1.733 47.28 
Begusarai 2,939,764 487 459 1.041 27.49 
Khagaria 1,666,886 393 344 1.376 0.418 
Patna 5,772,300 289 259 0.299 690.75 
W.Champaran 2,776,365 166 128 0.307 326.95 
Total 26,978,925 6,081 5,379 1.329 4143.7# 
* Block populations from 2011 Indian Census [35] 
# p-value<0.0001 at 7 degrees of freedom, indicating statistically significant difference between 
identified case burdens and expected case burdens based on district populations 
 
Table 3: Identified VL case burden by age group 
Age group 
(years) 
Population* Number of cases Ratio (per 100,000) 
0-4 3,508,474 362 10.32 
5-9 4,123,615 934 22.65 
10-14 3,776,045 1,050 27.81 
15-19 2,516,831 554 22.01 
20-24 2,186,709 400 18.29 
25-29 2,101,279 431 20.51 
30-34 1,949,196 452 23.19 
35-39 1,766,119 385 21.80 
40-44 1,396,862 327 23.41 
45-49 1,156,831 263 22.73 
50-54 901,989 228 25.28 
55-59 763,541 160 20.95 
60-64 818,092 215 26.28 
65-69 547,191 109 19.92 
70-74 358,440 30 8.37 
75-79 140,327 10 7.13 
80+ 170,996 13 7.60 
* Population age distribution for the 8 study districts, taken from [33] 
 
 
Table 4:  District-specific summary statistics for onset-to-diagnosis times, 
onset-to-treatment times and mortality used in regression analyses 
 Onset-to-diagnosis time 
(days) (N=4,234) 
Onset-to-treatment time 
(days) (N=4,145) 
Mortality  
(N=4,628) 
Mean Median IQR Mean Median IQR Number Died % died % of deaths 
Saharsa 36.58 31 19-44 34.17 30 20-40 1,181 43 3.64 26.06 
E. Champaran 51.00 42 28-63 51.22 42 29-61 1,136 45 3.96 27.27 
Samastipur 37.67 30 19-46 36.52 30 20-45 743 21 2.83 12.73 
Gopalganj 47.52 35 18-61 46.70 34 17-60 620 26 4.19 15.76 
Begusarai 22.50 16.5 7-32 21.99 17 7-31 356 14 3.93 8.48 
Khagaria 37.18 30 20-43 34.43 30 20-38 294 6 2.04 3.64 
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Patna 48.95 38 27-62 44.54 35 23-59 223 9 4.04 5.45 
W.Champaran 59.22 55 30.5-
80 
59.33 45 25-90 75 1 1.33 0.61 
All 8 districts 41.95 31 20-56 40.85 30 20-53 4,628 165 3.57 100 
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Table 5: Rate-ratios (and 95% confidence intervals) for VL patients’ onset-to-diagnosis (OD) and onset-to-treatment (OT) 
times for different factors, from multivariable negative-binomial regression models. Bihar, 2012-2013 
Variable Onset-to-diagnosis time (N=4,234) Onset-to-treatment time (N=4,145) 
No. of 
patients 
Rate-ratio (95% CI) p-value No. of patients Rate-ratio (95% CI) p-value 
Age Each 1-year 
increase 
4,234 1.003 (1.002-1.004) <10-4 4,145 1.003 (1.002-1.004) <10-4 
District* Saharsa 956 1.99 (1.82-2.18) <10-4 927 1.94 (1.77-2.12) <10-4 
E. Champaran 1,108 2.26 (2.07-2.47) <10-4 1,102 2.33 (2.14-2.54) <10-4 
Samastipur 710 2.17 (1.97-2.39) <10-4 682 2.16 (1.97-2.38) <10-4 
Gopalganj 572 2.28 (2.01-2.45) <10-4 567 2.28 (2.07-2.51) <10-4 
Begusarai 326 - - 318 - - 
Khagaria 291 1.61 (1.44-1.80) <10-4 277 1.56 (1.40-1.74) <10-4 
Patna 195 1.85 (1.63-2.10) <10-4 194 1.76 (1.55-1.99) <10-4 
W. Champaran 76 2.75 (2.30-3.27) <10-4 78 2.74 (2.29-3.28) <10-4 
Wall#  
 
Grass+straw 2,034 1.05 (0.97-1.12) 0.220 1,994 1.07 (0.99-1.14) 0.077 
Mud 478 - - 469 - - 
Mud, stone 812 1.10 (1.02-1.20) 0.014 787 1.14 (1.06-1.23) 0.001 
Concrete 910 1.004 (0.93-1.09) 0.916 895 1.01 (0.94-1.09) 0.752 
No. of pre- 
diagnosis  
treatments 
0 23 - - 39 - - 
1 1,585 1.64 (1.22-2.21) <10-4 1,548 0.78 (0.61-0.98) 0.032 
2 1,452 2.18 (1.62-2.94) <10-4 1,407 1.04 (0.82-1.31) 0.758 
3 748 2.99 (2.22-4.03) <10-4 736 1.37 (1.09-1.74) 0.008 
4 426 3.70 (2.73-5.00) <10-4 415 1.71 (1.35-2.17) <10-4 
Lower Caste No 2,943 - - - - - 
Yes 1,291 0.95 (0.91-0.99) 0.029 -   
Treatment 
cost 
Free - - - 3,379 - - 
Paid - - - 766 0.92 (0.87-0.97) 0.003 
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Same-district 
diagnosis 
No 332 - - 321 - - 
Yes 3,902 0.92 (0.85-0.99) 0.037 3,824 0.90 (0.83-0.98) 0.011 
Same-block 
diagnosis 
No - - - 1,850 - - 
Yes - - - 2,295 0.95 (0.905-0.995) 0.032 
* Baseline is Begusarai as district with shortest average OD and OT waiting times  
# Baseline is mud-walled housing as housing type with shortest average OT waiting time 
 
 
Table 6: Comparison of age-specific death rates in VL patients and in Bihar population. 
Age group VL patients (2012) Deaths (2012) Deaths per 1,000 VL cases per year Pop. deaths per 1,000 per year (2012)*  
Male Female Total Male Female Total Male Female Total Male Female Total 
0-4 84 116 200 2 8 10 23.81 68.97 50.00 11.2 11.8 11.5 
5-14 649 556 1205 5 18 23 7.70 32.37 19.09 0.9 0.8 0.9 
15-59 1234 777 2011 60 32 92 48.62 41.18 45.75 3.2 2.6 2.9 
60+ 174 51 225 26 3 29 149.43 58.82 128.89 42.9 49.0 45.7 
*From [36] 
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Table 7:  Odds-ratios (and 95% confidence intervals) for VL patients’ risk of 
death for different factors, from multivariable logistic regression model. 
Bihar, 2012-2013 (N=4,628) 
Variable 
 
No. of patients Odds-ratio 
 
95% CI 
 
p-value 
 Total Dead 
Age Each 1-year 
increase 
4,628 165 1.03  1.025-1.04 <10-4 
District Saharsa 1,181 43 2.65 1.07-6.57 0.036 
E. Champaran 1,136 45 2.60 1.04-6.48 0.040 
Samastipur 743 21 1.58 0.60-4.15 0.357 
Gopalganj 620 26 2.96 1.11-7.85 0.029 
Begusarai 356 14 3.22 1.16-8.91 0.025 
Khagaria 294 6 - - - 
Patna 223 9 1.85 0.62-5.53 0.272 
W. Champaran 75 1 0.71 0.08-6.18 0.754 
Onset-to-treatment 
time 
Each 1-day 
increase 
4,628 165 1.006 1.002-1.009 0.002 
Treatment duration Each 1-day 
increase 
0.91 0.89-0.93 <10-4 
Cattle owner  No 1,767 79 - - - 
Yes 2,861 86 0.61 0.44-0.85 0.004 
Paid for test Paid 1,980 53 - - - 
Free 2,648 112 2.19 1.49-3.21 <10-4 
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 151 cases with PKDL excluded 
6081 suspected VL cases identified 
5379 cases with onset 1st Jan 2012 - 30th Jun 2013 
4234 cases 
with all risk 
factor data 
551 cases with onset before 1st Jan 
2012 or after 30th Jun 2013 excluded 
1008 cases missing 
some risk factors 
414 cases 
missing OT time 
Chi-squared test 
for variation in 
district case 
burdens 
Multivariable
NB regression 
of OD times 
5923 cases with age and sex 
Chi-squared 
tests for 
variation in 
case burdens 
by age and sex 
137 cases 
missing OD time 
4965 cases 
with OT time 
Multivariable
NB regression 
of OT times 
749 cases missing 
some risk factors 
4628 cases with all 
risk factor data for 
mortality regression 
Multivariable 
logistic regression 
of mortality 
4145 cases 
with all risk 
factor data 
820 cases missing 
some risk factors 
2 cases without 
mortality status 
5377 cases with 
mortality status 
5930 cases without PKDL 
7 cases without age 
Single-
variable NB 
regressions 
5242 cases 
with OD time 
Single-variable 
logistic 
regressions 
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